| Dr Michael P Lorek, MD | |
|
700 2nd St Ne, Kaiser Permanente Capitol Hill Medical Center, Washington, DC 20002-8100 | |
| (202) 346-3000 | |
| Not Available |
| Full Name | Dr Michael P Lorek |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 48 Years |
| Location | 700 2nd St Ne, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134289648 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 0101032702 (Virginia) | Secondary |
| 207R00000X | Internal Medicine | D25896 (Maryland) | Secondary |
| 207N00000X | Dermatology | MD12541 (District Of Columbia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Mid-atlantic States,inc | 3779495858 | 1673 |
| Kaiser Foundation Health Plan Of The Mid-atlantic States,inc | 3779495858 | 1673 |
News Archive
Phase IV clinical research is growing rapidly, meaning expanding budgets for post-marketing research studies. And more of that work is being done by third parties and specialized vendors, according to a new study from Cutting Edge Information.
Today's headlines include reports about how health entitlement programs are faring in the ongoing deficit-reduction negotiations.
Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.
Early this morning, the U.S. Senate voted for cloture on the manager's amendment which includes abortion language that would force the federal government to pay premiums for private health plans that will cover any or all abortions while doing nothing to protect individual conscience rights.
› Verified 5 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
Phase IV clinical research is growing rapidly, meaning expanding budgets for post-marketing research studies. And more of that work is being done by third parties and specialized vendors, according to a new study from Cutting Edge Information.
Today's headlines include reports about how health entitlement programs are faring in the ongoing deficit-reduction negotiations.
Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.
Early this morning, the U.S. Senate voted for cloture on the manager's amendment which includes abortion language that would force the federal government to pay premiums for private health plans that will cover any or all abortions while doing nothing to protect individual conscience rights.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael P Lorek, MD 2101 E Jefferson St, Kaiser Permanente Medicare Enrollment, Rockville, MD 20852-4908 Ph: (301) 816-2424 | Dr Michael P Lorek, MD 700 2nd St Ne, Kaiser Permanente Capitol Hill Medical Center, Washington, DC 20002-8100 Ph: (202) 346-3000 |
News Archive
Phase IV clinical research is growing rapidly, meaning expanding budgets for post-marketing research studies. And more of that work is being done by third parties and specialized vendors, according to a new study from Cutting Edge Information.
Today's headlines include reports about how health entitlement programs are faring in the ongoing deficit-reduction negotiations.
Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.
Early this morning, the U.S. Senate voted for cloture on the manager's amendment which includes abortion language that would force the federal government to pay premiums for private health plans that will cover any or all abortions while doing nothing to protect individual conscience rights.
› Verified 5 days ago
Dr. George Walter Turiansky, MD Dermatology Medicare: Medicare Enrolled Practice Location: Walter Reed Army Medical Center; Attn: Mchl-mao-c, 6900 Georgia Ave. Nw, Washington, DC 20307 Phone: 202-782-7341 | |
Lauren Mckelroy, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2141 K St Nw Ste 307, Washington, DC 20037 Phone: 202-293-3990 | |
Dr. Catharine Lisa Kauffman, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3301 New Mexico Ave Nw, Suite #210, Washington, DC 20016 Phone: 202-363-9600 Fax: 202-363-9601 | |
Dr. Melissa Bueche Scorza, M.D Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6900 Georgia Ave Nw, Washington, DC 20307 Phone: 202-782-6173 | |
Dr. Edward H Stolar, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1712 Eye Street Nw, Suite 712, Washington, DC 20006 Phone: 202-659-2223 Fax: 202-659-0289 | |
Dr. Clinzo P. Mickle Ii, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 650 Pennsylvania Ave Se, Suite 420, Washington, DC 20003 Phone: 202-547-9001 | |
Dr. Urvi Pajvani Gonzales, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1120 19th St Nw, Suite 250, Washington, DC 20036 Phone: 202-955-6995 Fax: 202-955-3915 |